from Lonza Group AG (isin : CH0013841017)
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Lonza Group AG / Key word(s): Partnership/Agreement
Basel, Switzerland, 22 October 2024 – Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today a long-term extension of its collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. The extended agreement will expand the dedicated bioconjugation footprint for the customer through the construction of a new bioconjugation suite at Lonza’s Ibex® Biopark in Visp (CH). In addition, Lonza will provide commercial-scale monoclonal antibody (mAb) manufacturing services for a new ADC therapy. The new Visp bioconjugation suite will occupy approximately 800m2 of manufacturing space and will support the manufacture, handling, and containment of highly-potent modalities. The new suite is expected to be operational in 2027 and will generate approximately 100 new jobs. The customer-dedicated suite further extends Lonza’s relationship with the customer, which already consists of an integrated supply of the highly potent payload, drug-linker, commercial mAb manufacturing, conjugation services, and DP filling for the ADC molecule targeting hard-to-treat cancers. Based on an established relationship grounded in quality and delivery, the collaboration has also been extended to include long-term manufacturing services for a new ADC targeting solid tumors. Under the terms of the new agreement, Lonza will manufacture the mAb at Lonza’s biologics facility in Porriño (ES), occupying a majority of the site’s manufacturing capacity. The ADC will then be conjugated in the new dedicated large-scale bioconjugation suites in Visp (CH). Christian Morello, Vice President, Head of Bioconjugates, Lonza, commented: “The relationship with our valued partner has evolved over the years to incorporate all stages of bioconjugate manufacturing and commercialization. Offering end-to-end ADC manufacturing services eliminates supply chain complexities and streamlines product delivery at scale. The extension of our collaboration reflects our ability to meet our customers’ needs with operational expertise, innovative solutions, and flexible business models.” Jean-Christophe Hyvert, President, Biologics, Lonza, added: “Bioconjugates represent an exciting modality poised for substantial growth in the coming years driven by market demand, increased therapeutic efficacy, and access to novel disease targets. Our expanded relationship with this major biopharmaceutical company highlights the value of our services and our leading role in the global bioconjugates and ADC markets. The portfolio expansion is also a result of our network strategy, including our recent global expansion of large-scale commercial manufacturing capacity.” ADCs are bioconjugates that usually combine a targeting antibody with a highly-potent payload using a linker molecule. By using targeted delivery to cancer cells while limiting toxicity to healthy tissues, they are fulfilling their therapeutic and commercial potential by transforming treatment options and bringing hope to cancer patients. Lonza has unique experience in supporting ADC manufacturing, from early development stages to commercial launch, including drug substance manufacturing and drug product filling. As a leading CDMO for bioconjugates, Lonza has produced more than 1,000 cGMP batches for more than 70 programs since 2006. About Lonza Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments. Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 893 million in Half-Year 2024. Find out more at www.lonza.com Lonza Contact Details Victoria Morgan Dr. Martina Ribar Hestericová Daniel Buchta Additional Information and Disclaimer Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release. All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third-party owners and are used only for informational purposes. Privacy Policy link End of Media Release |
| Language: | English |
| Company: | Lonza Group AG |
| Münchensteinerstrasse 38 | |
| 4052 Basel | |
| Switzerland | |
| Phone: | +4161 316 81 11 |
| Internet: | www.lonza.com |
| ISIN: | CH0013841017 |
| Valor: | 1384101 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 2004441 |
| End of News | EQS News Service |
2004441 22.10.2024 CET/CEST